Literature DB >> 33373659

Small Animal IMRT Using 3D-Printed Compensators.

Gage Redler1, Erik Pearson2, Xinmin Liu2, Inna Gertsenshteyn2, Boris Epel2, Charles Pelizzari2, Bulent Aydogan2, Ralph Weichselbaum2, Howard J Halpern2, Rodney D Wiersma3.   

Abstract

PURPOSE: Preclinical radiation replicating clinical intensity modulated radiation therapy (IMRT) techniques can provide data translatable to clinical practice. For this work, treatment plans were created for oxygen-guided dose-painting in small animals using inverse-planned IMRT. Spatially varying beam intensities were achieved using 3-dimensional (3D)-printed compensators. METHODS AND MATERIALS: Optimized beam fluence from arbitrary gantry angles was determined using a verified model of the XRAD225Cx treatment beam. Compensators were 3D-printed with varied thickness to provide desired attenuation using copper/polylactic-acid. Spatial resolution capabilities were investigated using printed test-patterns. Following American Association of Physicists in Medicine TG119, a 5-beam IMRT plan was created for a miniaturized (∼1/8th scale) C-shape target. Electron paramagnetic resonance imaging of murine tumor oxygenation guided simultaneous integrated boost (SIB) plans conformally treating tumor to a base dose (Rx1) with boost (Rx2) based on tumor oxygenation. The 3D-printed compensator intensity modulation accuracy and precision was evaluated by individually delivering each field to a phantom containing radiochromic film and subsequent per-field gamma analysis. The methodology was validated end-to-end with composite delivery (incorporating 3D-printed tungsten/polylactic-acid beam trimmers to reduce out-of-field leakage) of the oxygen-guided SIB plan to a phantom containing film and subsequent gamma analysis.
RESULTS: Resolution test-patterns demonstrate practical printer resolution of ∼0.7 mm, corresponding to 1.0 mm bixels at the isocenter. The miniaturized C-shape plan provides planning target volume coverage (V95% = 95%) with organ sparing (organs at risk Dmax < 50%). The SIB plan to hypoxic tumor demonstrates the utility of this approach (hypoxic tumor V95%,Rx2 = 91.6%, normoxic tumor V95%,Rx1 = 95.7%, normal tissue V100%,Rx1 = 7.1%). The more challenging SIB plan to boost the normoxic tumor rim achieved normoxic tumor V95%,Rx2 = 90.9%, hypoxic tumor V95%,Rx1 = 62.7%, and normal tissue V100%,Rx2 = 5.3%. Average per-field gamma passing rates using 3%/1.0 mm, 3%/0.7 mm, and 3%/0.5 mm criteria were 98.8% ± 2.8%, 96.6% ± 4.1%, and 90.6% ± 5.9%, respectively. Composite delivery of the hypoxia boost plan and gamma analysis (3%/1 mm) gave passing results of 95.3% and 98.1% for the 2 measured orthogonal dose planes.
CONCLUSIONS: This simple and cost-effective approach using 3D-printed compensators for small-animal IMRT provides a methodology enabling preclinical studies that can be readily translated into the clinic. The presented oxygen-guided dose-painting demonstrates that this methodology will facilitate studies driving much needed biologic personalization of radiation therapy for improvements in patient outcomes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33373659      PMCID: PMC8122034          DOI: 10.1016/j.ijrobp.2020.12.028

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   8.013


  52 in total

1.  Variations of the hypoxic fraction in the SCC VII tumors after single dose and during fractionated radiation therapy: assessment without anesthesia or physical restraint of mice.

Authors:  Y Kitakabu; Y Shibamoto; K Sasai; K Ono; M Abe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-04       Impact factor: 7.038

Review 2.  Preclinical mouse cancer models: a maze of opportunities and challenges.

Authors:  Chi-Ping Day; Glenn Merlino; Terry Van Dyke
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

Review 3.  Translation of research evidence from animals to humans.

Authors:  Daniel G Hackam; Donald A Redelmeier
Journal:  JAMA       Date:  2006-10-11       Impact factor: 56.272

4.  Development and validation of a treatment planning system for small animal radiotherapy: SmART-Plan.

Authors:  Stefan J van Hoof; Patrick V Granton; Frank Verhaegen
Journal:  Radiother Oncol       Date:  2013-10-31       Impact factor: 6.280

5.  Characterization of image quality and image-guidance performance of a preclinical microirradiator.

Authors:  R Clarkson; P E Lindsay; S Ansell; G Wilson; S Jelveh; R P Hill; D A Jaffray
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

Review 6.  Small animal radiotherapy research platforms.

Authors:  Frank Verhaegen; Patrick Granton; Erik Tryggestad
Journal:  Phys Med Biol       Date:  2011-05-26       Impact factor: 3.609

7.  A technique for the quantitative evaluation of dose distributions.

Authors:  D A Low; W B Harms; S Mutic; J A Purdy
Journal:  Med Phys       Date:  1998-05       Impact factor: 4.071

Review 8.  Monte Carlo systems used for treatment planning and dose verification.

Authors:  Lorenzo Brualla; Miguel Rodriguez; Antonio M Lallena
Journal:  Strahlenther Onkol       Date:  2016-11-25       Impact factor: 3.621

9.  Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals.

Authors:  Hu Zhou; Manuel Rodriguez; Fred van den Haak; Geoffrey Nelson; Rahil Jogani; Jiali Xu; Xinzhi Zhu; Yongjiang Xian; Phuoc T Tran; Dean W Felsher; Paul J Keall; Edward E Graves
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-13       Impact factor: 7.038

10.  Towards Human Oxygen Images with Electron Paramagnetic Resonance Imaging.

Authors:  Boris Epel; Gage Redler; Victor Tormyshev; Howard J Halpern
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

View more
  1 in total

1.  Intensity Modulated High Dose Rate (HDR) Brachytherapy Using Patient Specific 3D Metal Printed Applicators: Proof of Concept.

Authors:  James J Sohn; Mitchell Polizzi; Sang-Won Kang; Woo-Hyeong Ko; Yong-Hyun Cho; Keun-Yong Eom; Jin-Beom Chung
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.